Moderna Remaking Itself as mRNA Startup Incubator

June 12, 2014 | With over $400 million on hand, Cambridge-based Moderna Therapeutics is revisiting its role in bringing mRNA-based therapies to market. While it had originally planned to create both an mRNA platform, and a series of drug programs, Moderna now sees itself as a serial spin-out creator, working internally on its platform while parenting new companies to develop its best drug prospects. Moderna says that several of these companies have already been formed, though only one, the cancer-focused Onkaido Therapeutics, has so far been publicly announced. Xconomy